A recent study reveals that patients who stop using blockbuster GLP-1 drugs like Mounjaro or Wegovy can put back on shed pounds at a significantly accelerated pace than those who halt conventional diet and exercise programs.
Published data in a prominent health publication points out that while overweight people often shed substantial amounts of their body weight while using the jabs, the mass returns at an average rate of 0.8 kg per month after stopping.
"People buying these drugs should be aware of the risk of quick weight regain when the medication ends," stated lead investigator Dr. Susan Jebb.
This pace of recovery suggests a return to pre-treatment weight in about 18 months.
Comparing Approaches
The study, which reviewed dozens of trials involving thousands of participants, contrasted the outcomes of these new drugs with older methods.
The team point out that people who shed pounds through lifestyle changes alone generally see a less rapid creep back—approximately 100 grams monthly—post-intervention.
Explaining the Rapid Rebound
Nutrition scientists suggest the way of the injections explains the amplified weight return.
These medications imitate a natural hormone called GLP-1, which controls feelings of fullness.
"Long-term administration of the hormone concentrations several times higher than normal might result in the body to produce less of its own natural GLP-1, and may also diminish sensitivity to its effects," noted Dr. Adam Collins, a nutrition researcher.
"Stopping of this medication leads to hunger is no longer kept in check, making excessive eating a significant risk."
An Ongoing Disease?
Medical guidelines recommend the jabs for individuals with obesity-related health risks, accompanied by prescribed lifestyle changes.
Many experts argue that, due to the high risk of relapse, the therapy is often ongoing.
This opinion is reinforced by pharmaceutical companies, who note that the findings "highlight the long-term nature of obesity," akin to managing conditions like diabetes.
Patient Accounts
People who have discontinued the medication explain a intense return of cravings.
"It felt as if something that goes on and I was suddenly starving," said an individual.
The struggle is worsened if individuals have not established permanent lifestyle or habit modifications during therapy.
Significant Adoption
Figures show that a significant number of adults in the UK have tried these injections in the last 12 months, with demand remaining high.
- Adoption is more common among women compared to men.
- The middle-aged age group shows the highest usage rates.
- Many obtain the medications through private prescriptions rather than public health services.
Finally, researchers stress that while GLP-1 drugs are powerful tools for weight loss, they are not a standalone solution and lasting health benefits relies on combined lifestyle management.
